Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Micrometastatic bone marrow involvement: detection and prognostic significance
Autore:
Braun, S; Pantel, K;
Indirizzi:
Univ Munich, Klinikum Innenstadt, Frauenklin, D-80337 Munich, Germany UnivMunich Munich Germany D-80337 , Frauenklin, D-80337 Munich, Germany
Titolo Testata:
MEDICAL ONCOLOGY
fascicolo: 3, volume: 16, anno: 1999,
pagine: 154 - 165
SICI:
1357-0560(199909)16:3<154:MBMIDA>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
POLYMERASE CHAIN-REACTION; BREAST-CANCER CELLS; EPITHELIAL MEMBRANE ANTIGEN; DISSEMINATED TUMOR-CELLS; MONOCLONAL-ANTIBODIES; IMMUNOCYTOCHEMICAL DETECTION; COLORECTAL-CANCER; GASTRIC-CANCER; GENETIC DIAGNOSIS; MICRO-METASTESES;
Keywords:
solid tumors; micrometastases; bone marrow; tumor staging; adjuvant therapy;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
89
Recensione:
Indirizzi per estratti:
Indirizzo: Pantel, K Univ Hamburg, Klinikum Eppendorf, Frauenklin, Martinistr 52, D-20246 Hamburg, Germany Univ Hamburg Martinistr 52 Hamburg Germany D-20246 urg, Germany
Citazione:
S. Braun e K. Pantel, "Micrometastatic bone marrow involvement: detection and prognostic significance", MED ONCOL, 16(3), 1999, pp. 154-165

Abstract

The present review focuses on the methodology and clinical significance ofnew diagnostic approaches to identify individual cancer cells present in bone marrow, both as a frequent site of metastasis formation and an indicator organ for hematogenous tumor cell dissemination. The steadily increasing number of studies on this issue is characterized by considerable methodological variations of important variables, such as the size of the study population, and the reliability of monoclonal antibodies used for tumor cell detection. Emerging data indicate that this disturbing heterogeneity might be overcome by the use of reliable and specific anti-cytokeratin antibodies (for example, A45-B/B3) as, for the time, standard markers for the detection of micrometastatic tumor cells in bone marrow. Prospective clinical studieshave shown that immunoassays based on anti-CK antibodies identify patients' subgroups with a poor clinical prognosis with regard to early metastasis manifestation and reduced overall survival in various epithelial tumor entities, including breast, colon, rectum, stomach, esophagous, prostate, renal, bladder, and nonsmall cell lung cancer. The immunocytochemical assays maybe therefore used to improve tumor staging with potential consequences foradjuvant therapy, because disseminated cells appeared to be dormant, non-cycling (for example Ki-67 antigen-negative) cells, suggesting a resistence to cell-cycle dependent therapy, such as chemotherapy. Therefore, cell-cycle independent antibody-based immunotherapy might be an interesting option to complement chemotherapy. Another promising clinical application is monitoring the response of micrometastatic cells to adjuvant therapies, which, atpresent, can only be assessed retrospectively after an extended period of clinical followup. The outlined current strategies for detection and characterization of cancer micrometastasis might help to design and control new therapeutic strategies for secondary prevention of metastatic relapse in patients with operable primary carcinomas.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/12/20 alle ore 22:53:55